Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges. (12th January 2021)

• Record Type: Journal Article
• Authors: Krishnamoorthy, Mithunah; Lenehan, John G; Maleki Vareki, Saman
• Is Part Of: Journal of the National Cancer Institute. Volume 113:Number 7(2021)
• Page Start: 823
• Page End: 832
• Publication Date: 2021-01-12
• Subjects: Cancer -- Periodicals; Cancer -- Research -- Periodicals; 616.994
• DOI: 10.1093/jnci/djaa216
• Languages: English
• ISSNs: 0027-8874

Abstract

Abstract: Neoadjuvant immunotherapy involves administering immune checkpoint inhibitors before surgical resection in high-risk resectable disease. This strategy was shown to have a high pathological response rate and prolonged relapse-free survival in randomized trials in melanoma, glioblastoma, and colon cancer with small numbers of patients. In resectable cancers, immune checkpoint inhibitors such as anti-programmed cell death-1 (PD1) and anti-cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) can enhance antitumor immunity by activating antigen-specific T cells found in the primary tumor. These tumor-reactive T cells continue to exert antitumor effects on remaining neoplastic cells after the resection of the primary tumor, potentially preventing relapses from occurring. Based on the scientific rationale and early clinical observations with surrogate survival endpoints, neoadjuvant immunotherapy may provide an effective alternative to other therapeutic strategies such as adjuvant treatment. However, this can be determined only by conducting randomized controlled trials comparing neoadjuvant immunotherapy with the current standard of care for each tumor site. This review discusses the cellular mechanisms that occur during successful neoadjuvant immunotherapy and highlights the clinical data from the available human studies that support the preclinical mechanistic data. Here we also discuss strategies required for successful neoadjuvant immunotherapy, including combination treatment strategies and resistance mechanisms to neoadjuvant treatment.